York and Scarborough Teaching Hospitals NHS Foundation Trust R&I Department SOP Pharm/S51



Expiry Date Extensions and Re-labelling of IMPs

IT IS THE RESPONSIBILITY OF <u>ALL</u> USERS OF THIS SOP TO ENSURE THAT THE CORRECT VERSION IS BEING USED

All staff should regularly check the R&I Department's website and/or Q-Pulse for information relating to the implementation of new or revised versions. Staff must ensure that they are adequately trained in the new procedure and must make sure that all copies of superseded versions are promptly withdrawn from use unless notified otherwise by the SOP Controller.

The definitive versions of all R&I Department SOPs appear online. If you are reading this in printed form check that the version number and date below is the most recent one as shown on the R&I Department website:

www.research.yorkhospitals.nhs.uk/sops-and-guidance-/ and/or Q-Pulse

SOP Reference: Pharm/S51

Version Number: 4.0

Author: Rachel Spooner Implementation date of current version: 7th July 2025

Approved by: Name/Position: Poppy Cottrell-Howe, Pharmacy Clinical Trials

Manager

Date: 9th June 2025

Name/Position: Sarah Sheath, SOP Controller

Date: 9th June 2025

This SOP will normally be reviewed every 3 years unless changes to the legislation require otherwise

Version History Log

This area should detail the version history for this document. It should detail the key elements of the changes to the versions.

Version	Date Implemented	Reviewers	Details of significant changes	
1.0	1 st September 2016			
2.0	8 th March 2019		Change of author. Change of link to R&D website	
3.0	26 th July 2022		Update of staff able to perform relabelling tasks.	
4.0	7 th July 2025	Rachel Spooner	Change of author. Clarification on the staff members that should complete relabelling.	

Version 4.0 Contents

Contents

		Page No
1	Introduction, Background and Purpose	1
2	Who Should Use This SOP	1
3	When this SOP Should be Used	1
4	Procedure(s)	2
5	Related SOPs and Documents	3

Version 4.0 Contents

1 Introduction, Background and Purpose

On occasion the Sponsor of a clinical trial will receive new information which will allow them to extend the expiry date of an Investigational Medicinal Product (IMP) which is already in circulation. In this case the Sponsor will contact the participating site in writing, giving a procedure and relevant documentation for the process of relabelling the trial Investigational Medicinal Product with the new expiry date – this must include a list of batch numbers (and for individually numbered packs- the pack numbers) to be re-labelled.

The extension and re-labelling process may be carried out by a monitor sent by the Sponsor, working under the supervision of a clinical trials technician/ pharmacy clinical trials manager. If the procedure requires an expiry date extension to be carried out on site by Trust staff this will be performed by a Clinical Trial Pharmacy Technician and checked by an ACT-accredited clinical trials technician that has appropriate clinical trials training and experience performing a final check.

Re-labelling of different batches/products must be segregated so that only one product and batch is re-labelled at any one time. An area check will be performed at the beginning of the re-labelling process and a label reconciliation check at the end of the process to ensure that all packs are assembled and re-labelled correctly before proceeding further.

The re-labelling process will be recorded on form Pharm/F117 in addition to any documentation provided by the Sponsor.

2 Who Should Use This SOP

This procedure should be followed by all members of the clinical trials team within the pharmacy department at York and Scarborough Hospitals, which form part of the York and Scarborough Teaching Hospitals NHS Foundation Trust.

3 When this SOP Should be Used

This SOP should be followed during the process of extending and re-labelling of expiry dates of Investigational Medicinal Products hosted or sponsored by York and Scarborough Teaching Hospitals NHS Foundation Trust.

Version 4.0 Page 1 of 3

4 Procedure(s)

4.1 Re-labelling

The below steps for re-labelling, including assembling of the products to be relabelled and the labels themselves must be carried out by a clinical trials pharmacy technician.

- Prepare an area to carry out the re-labelling. Ensure that this area is free from any items and labels.
- Assemble the original IMP packs to be over labelled according to the documentation provided by the Sponsor.
- Assemble the labels provided by the Sponsor.
- Complete the required information on Pharm/F117 and the worksheet provided by the sponsor.
- Attach the first and last label from each page of the labels provided to the back of Pharm/F117 if possible (and on the worksheet provided by the Sponsor, if requested to do so).
- Carry out the re-labelling.
- The labels should be placed next to the original expiry date (unless otherwise instructed by the Sponsor). Take care that any peelable patient information labels are not impeded by the re-labelling. Do not cover the original batch number or pack numbers (where applicable).
- Complete the "label reconciliation" part of Pharm/F117 and worksheet provided by the Sponsor.
- If there are any discrepancies with the IMP or label accountability or between the Sponsor documentation and the worksheet these must be recorded and accounted for on Pharm/F117.
- Complete the 're-labelling performed by' section of Pharm/F117.
- The trial monitor or ACT-accredited clinical trial pharmacy technician must perform the release check following the steps in section 4.2.
- Once the batch has been released, the re-labelled IMP may be returned to the correct storage area ready for use.
- Fulfil any of the sponsor's requirements for the completed paperwork.
- Record this activity for costing purposes by recording this activity on EDGE if applicable.
- Pharm/F117 and the Sponsors re-labelling documentation will be stored in the Pharmacy trial file.

4.2 Checking Process

The re-labelling process must be checked by an ACT-accredited clinical trial pharmacy technician who are competent to complete final checks of clinical trial items, if the study monitor is not present to complete the check.

The following checks must be carried out:

Check of the re-labelling area and assembled products -

- Stock assembled is for the correct clinical trial.
- Correct IMP and strength assembled.

Version 4.0 Page 2 of 3

- Batch numbers of IMP packs assembled is correct against the Sponsor's relabelling documentation.
- Only one batch of IMP has been assembled.
- Count the number of IMP assembled and check that this is correct against Sponsor's re-labelling documentation.
- The area is clear of any items which are not to be used for the batch being relabelled.
- Check of the labels assembled Check all information on the main body of the labels is exactly the same as that on the sample labels attached to Pharm/F117 (or sponsor provided worksheet).
- Check that the batch number and expiry date on the label is correct.
- Check that the pack numbers on the labels match those on the assembled packs (where applicable).
- Check the labels are aligned correctly.
- Count the number of labels used, and any excess labels not used.
- Check that the information on the labels matches that on the Sponsor's documentation.
- Final release of the re-labelled products Check that form Pharm/F117 and the Sponsor's provided worksheet are completed in full.
- Check the IMP to ensure that the correct drug, strength and batch have been used.
- Count the number of IMP packs that have been re-labelled.
- Check that the correct label has been applied to each IMP pack.
- Check that the positioning of each label has been applied to the right area.
- Perform the label reconciliation check and destroy any unused labels.
- Where the IMP is individually numbered, check that the packs have been relabelled matches the inventory list provided by the sponsor.
- Also check that the pack number on the new label matches that on the original pack (where applicable).

Once all of the checks have been completed, complete the 'checked by' section of Pharm/F117

The IMP can then be returned to the appropriate storage area.

5 Related SOPs and Documents

Pharm/F117 Expiry Date Re-labelling Worksheet

Version 4.0 Page 3 of 3